UNSPSC 51414100: Vasodilator purines

Vasodilator drugs made from a series of heterocyclic compounds that are variously substituted in nature and are known also as purine bases.

UNSPSC 51414100 Vasodilator purines, a Class code, covers emergency and critical-care medications that state and local governments procure for fire rescue services, hospital systems, and public health programs. Recent solicitations show state and local buyers purchasing specific vasodilator and cardiac medications—adenosine, diltiazem, and related advanced life support drugs—in both direct single-jurisdiction procurements and cooperative multi-state purchasing arrangements. The issuing bodies span city fire departments, state health agencies, and multistate cooperative purchasing alliances; the City of Tampa's Fire Rescue and the Texas Health and Human Services Commission appear as recent active buyers. Work under the code includes sealed-bid supply of regulated pharmaceuticals with strict expiration-date and quality-assurance requirements, participation in statewide or multistate cooperative frameworks that aggregate demand across multiple jurisdictions, and compliance with FDA manufacturing standards, OSHA safety documentation, and federal accessibility requirements (WCAG 2.2 Level AA and Section 508).

Geographic activity centers on Florida, Texas, and Minnesota, with additional reach into Oregon through cooperative purchasing. The City of Tampa issued IFB 26P00188 for Advanced Life Support Medications (Labetalol, Epinephrine, Adenosine, and Diltiazem) with a response deadline of April 8, 2026 and an estimated contract value of $40,000.00, designating a Small Local Business Enterprise sheltered market with a 5 percent bid discount. The Texas Health and Human Services Commission posted RFI HHS0017013 on April 3, 2026, to gather vendor capabilities for a direct-to-manufacturer prescription program, signaling early-stage state-level procurement design. The Minnesota Multistate Cooperative Purchasing Alliance (MMCAP) issued RFP S1070000015802 due March 26, 2026, for generic multi-source pharmaceuticals and OTC products distributed through authorized wholesalers, with contract effectiveness on July 1, 2026, and performance penalties of $200 to $1,500 per violation for non-compliance. Cooperative purchasing frames an increasing share of activity, offering larger aggregate volume but requiring compliance with multistate administrative standards, cGMP certification, and DSCSA chain-of-custody requirements.